UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 6-K
REPORT
OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month
of April, 2017
Commission
File Number: 001-36582
Auris Medical Holding AG
(Exact
name of registrant as specified in its charter)
Bahnhofstrasse
21
6300 Zug,
Switzerland
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Annual General Meeting Results
On April
13, 2017, Auris Medical Holding AG (“
Auris Medical
”) held its Annual General Meeting of Shareholders. The final
results of each of the agenda items submitted to a vote of the shareholders are as follows:
Agenda Item 1: Approval of
the annual report of Auris Medical Holding AG, the financial statements of Auris Medical Holding AG and the group consolidated
financial statements for the 2016 financial year
Auris Medical
shareholders approved the annual report of Auris Medical Holding AG, the financial statements of Auris Medical Holding AG and
the group consolidated financial statements for the 2016 financial year.
Agenda Item 2: Discharge of
liability for the members of the Board of Directors and the persons entrusted with the Corporation’s management
Auris Medical
shareholders approved the discharge of liability of the members of the Board of Directors and the persons entrusted with the Corporation’s
management for the 2016 financial year.
Agenda Item 3: Appropriation
of financial results
Auris Medical
shareholders approved to carry forward the loss for the 2016 financial year in the amount of CHF 3,393,256.
Agenda Item 4: Approval of
changes to the Articles of Association
Auris Medical
shareholders approved an increase in the authorized share capital to CHF 8,860,000 and the revision of Article 3a of the Articles
of Association.
Auris Medical
shareholders approved an increase in the conditional share capital for financing purposes to CHF 6,260,000, an increase in the
conditional share capital for equity incentive plans to CHF 2,600,000, and an amendment to Article 3b of the Articles of Association.
Agenda Item 5: Votes on compensation
for the members of the Board of Directors and the Executive Management Committee
Auris Medical
shareholders approved a maximum aggregate amount of compensation of CHF 800,000 (gross) for the members of the Board of Directors
for the period from the 2017 Annual General Meeting to the 2018 Annual General Meeting.
Auris Medical
shareholders approved a maximum aggregate amount of compensation of CHF 4,000,000 (gross) for the members of the Executive Management
Committee for the 2018 financial year.
Agenda Item 6: Re-election
of the Chairman and members of the Board of Directors. Election to the Board of Directors
Auris Medical
shareholders re-elected Thomas Meyer, PhD, as member and Chairman of the Board of Directors, re-elected Armando Anido, MBA, Oliver
Kubli, CFA, Berndt Modig, MBA, Antoine Papiernik-Berkhauer, MBA, and Calvin Roberts, MD, as members of the Board of Directors,
and elected Mats Peter Blom, MBA, as member of the Board of Directors, each for a term of one year ending upon completion of the
2018 Annual General Meeting.
Agenda Item 7: Re-election
and election to the Compensation Committee
Auris Medical
shareholders re-elected Armando Anido, MBA, and elected Calvin Roberts, MD, as members of the Compensation Committee, each for
a term of one year ending upon completion of the 2018 Annual General Meeting.
Agenda Item 8: Re-election
of the Auditors
Auris Medical
shareholders re-elected Deloitte AG as auditors of Auris Medical Holding AG for the 2017 financial year.
Agenda Item 9: Re-election
of the Independent Proxy
Auris Medical
shareholders re-elected Sandro G. Tobler, Attorney at Law, Zug, as Independent Proxy of Auris Medical Holding AG for a term of
one year ending upon completion of the 2018 Annual General Meeting.
INCORPORATION
BY REFERENCE
This Report on Form 6-K shall
be deemed to be incorporated by reference into the registration statements on Form F-3 (Registration Number 333-206710) and Form
S-8 (Registration Numbers 333-198037 and 333-200805) of Auris Medical Holding AG and to be a part thereof from the date on which
this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
Auris Medical Holding AG
|
|
|
|
|
|
|
|
|
|
By:
|
/s/ Anne Sabine Zoller
|
|
|
|
|
Name:
|
Anne Sabine Zoller
|
|
|
|
|
Title:
|
General Counsel
|
Date:
April 13, 2017
Auris Medical (NASDAQ:EARS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Auris Medical (NASDAQ:EARS)
Historical Stock Chart
From Apr 2023 to Apr 2024